Acute-to-Chronic Glycemic Ratio as a Predictor of COVID-19 Severity and Mortality.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
01 01 2022
Historique:
received: 24 06 2021
accepted: 27 10 2021
pubmed: 17 11 2021
medline: 11 1 2022
entrez: 16 11 2021
Statut: ppublish

Résumé

To evaluate the association between acute-to-chronic (A/C) glycemic ratio and mortality and severity outcomes for patients with type 2 diabetes (T2D) hospitalized with coronavirus disease 2019 (COVID-19). A total of 91 patients were included. We measured glycemia at admission and estimated the average chronic glucose levels to calculate the A/C glycemic ratio. The primary outcome was a composite of in-hospital mortality, intensive care unit admission, and mechanical ventilation. Thirty-five patients had a primary outcome event, presenting a significant association with the A/C glycemic ratio (hazard ratio [HR] 1.57 [95% CI 1.14-2.15], P = 0.005). In comparisons with the 2nd tertile, the 3rd tertile of the A/C glycemic ratio was associated with the primary outcome (HR 3.39 [95% CI 1.31-8.75], P = 0.012). In the multivariate analysis, after additional adjustment for age, sex, comorbidities, inflammatory markers, and corticosteroid therapy, the association for the 3rd tertile (HR 3.96 [95% CI 1.35-11.59], P = 0.012) remained significant. In patients with T2D hospitalized with COVID-19, the imbalance between acute glycemia at admission and chronic metabolic control is associated with worse prognosis.

Identifiants

pubmed: 34782352
pii: dc21-1321
doi: 10.2337/dc21-1321
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

255-258

Informations de copyright

© 2021 by the American Diabetes Association.

Auteurs

Jordi Ramon (J)

1Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.

Gemma Llauradó (G)

1Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
2Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
3Departament de Medicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.
4CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain.

Roberto Güerri (R)

2Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
3Departament de Medicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.
5Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.

Elisenda Climent (E)

1Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
2Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
3Departament de Medicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.

Silvia Ballesta (S)

1Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
2Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.

David Benaiges (D)

1Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
2Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
3Departament de Medicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.

Inmaculada López-Montesinos (I)

2Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
5Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.

Humberto Navarro (H)

1Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
3Departament de Medicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.

Natalia Fernández (N)

1Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.

Maria José Carrera (MJ)

1Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
3Departament de Medicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.

Dídac Mauricio (D)

4CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain.
6Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
7Department of Medicine, Faculty of Medicine, University of Vic - Central University of Barcelona, Vic, Spain.

Juana A Flores-Le Roux (JA)

1Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
2Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
3Departament de Medicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.

Juan-José Chillarón (JJ)

1Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
2Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
3Departament de Medicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH